IRIS UniCatt

Patrono, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.635
EU - Europa 2.522
AS - Asia 1.537
SA - Sud America 307
AF - Africa 33
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.594
CN - Cina 636
DE - Germania 574
SG - Singapore 496
SE - Svezia 489
IT - Italia 393
UA - Ucraina 323
BR - Brasile 266
IE - Irlanda 189
FR - Francia 135
GB - Regno Unito 130
ID - Indonesia 114
FI - Finlandia 81
RU - Federazione Russa 77
IN - India 70
TR - Turchia 33
CA - Canada 25
HK - Hong Kong 25
KR - Corea 25
VN - Vietnam 23
IR - Iran 19
BE - Belgio 17
AU - Australia 16
NL - Olanda 16
AT - Austria 13
CH - Svizzera 13
ES - Italia 13
PH - Filippine 13
CL - Cile 12
PK - Pakistan 12
AR - Argentina 11
PL - Polonia 11
NZ - Nuova Zelanda 10
IQ - Iraq 9
TH - Thailandia 9
CI - Costa d'Avorio 8
EG - Egitto 8
CZ - Repubblica Ceca 7
PE - Perù 7
SA - Arabia Saudita 7
BD - Bangladesh 6
MX - Messico 6
RO - Romania 6
ZA - Sudafrica 6
IL - Israele 5
JP - Giappone 5
CO - Colombia 4
LV - Lettonia 4
NO - Norvegia 4
NP - Nepal 4
SI - Slovenia 4
AL - Albania 3
AZ - Azerbaigian 3
DZ - Algeria 3
EC - Ecuador 3
JM - Giamaica 3
KZ - Kazakistan 3
LT - Lituania 3
MK - Macedonia 3
TN - Tunisia 3
UZ - Uzbekistan 3
VE - Venezuela 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
CR - Costa Rica 2
GE - Georgia 2
HU - Ungheria 2
KE - Kenya 2
KW - Kuwait 2
LI - Liechtenstein 2
MD - Moldavia 2
MY - Malesia 2
PT - Portogallo 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
DO - Repubblica Dominicana 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
LK - Sri Lanka 1
MA - Marocco 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
OM - Oman 1
QA - Qatar 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TW - Taiwan 1
Totale 7.064
Salva come PNG Salva come JPEG
Città #
Chandler 408
Ashburn 240
Singapore 221
Jacksonville 184
Dublin 175
San Mateo 156
Nanjing 133
Jakarta 112
Hangzhou 102
Wilmington 94
Beijing 92
Cattolica 87
Woodbridge 81
Ann Arbor 70
Boston 70
Lawrence 63
Rome 55
Moscow 51
Menlo Park 50
Milan 49
Houston 48
Redwood City 45
Nanchang 41
Dearborn 39
Fairfield 36
Princeton 35
Seattle 30
Bremen 26
Chicago 26
Mountain View 26
Redmond 26
Los Angeles 25
New York 25
Shenyang 24
Hebei 22
Kunming 22
Boardman 21
Izmir 20
Lancaster 20
Hong Kong 18
Bareggio 17
Brussels 17
Hefei 16
Tianjin 16
Guangzhou 15
São Paulo 15
Frankfurt am Main 13
Munich 13
Seoul 13
Hyderabad 12
London 12
University Park 12
Belo Horizonte 11
Jiaxing 11
Leawood 11
Norwalk 11
Nürnberg 11
Augusta 10
Hounslow 10
Philadelphia 10
Helsinki 9
Abidjan 8
Detroit 8
Hanoi 8
Nuremberg 8
Pune 8
Shanghai 8
Washington 8
Edinburgh 7
Guarulhos 7
Lanzhou 7
Quezon City 7
Rio de Janeiro 7
Campinas 6
Changsha 6
Toronto 6
Vienna 6
Vimercate 6
Andover 5
Ankara 5
Atlanta 5
Brasília 5
Busto Arsizio 5
Catania 5
Changchun 5
Lima 5
Marseille 5
Ottawa 5
Paris 5
San Francisco 5
São Bernardo do Campo 5
Bangkok 4
Brno 4
Chieti 4
Coyoacán 4
Düsseldorf 4
Florence 4
Garanhuns 4
Ho Chi Minh City 4
Indiana 4
Totale 3.555
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 166
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 153
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 151
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 138
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 135
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 129
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 127
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 126
Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis 124
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 115
Increased thromboxane biosynthesis in essential thrombocythemia. 112
Nutraceuticals in diabetes and metabolic syndrome. 112
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 110
Platelet activation and atherothrombosis 102
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 101
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 101
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 96
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 93
Drug insight: aspirin resistance- fact or fashion 92
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 90
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells 89
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 89
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 87
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective 86
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 85
Aspirin: promise and resistance in the new millennium. 84
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 84
Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C →T polymorphism 84
Antiplatelet therapy:aspirin for asymptomatic atherosclerosis? 83
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 80
Low-dose aspirin for the prevention of atherothrombosis 80
Non-steroidal anti-inflammatory drugs 79
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 79
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) 78
The future of antiplatelet therapy in cardiovascular disease 78
Platelet progenitors: the hidden drug target 77
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 75
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 74
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 73
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 73
Aspirin 72
Aspirin 72
Low-Dose Aspirin, Coxibs, and other NSAIDS: A clinical Mosaic Emerges. 71
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 71
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials 71
Fourth universal definition of myocardial infarction (2018) 70
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 70
Determinants of platelet activation in Alzheimer's disease. 69
The coxibs, selective inhibitors of cyclooxygenase-2 68
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 68
Determinants of the interindividual variability in response to antiplatelet drugs. 66
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 63
Aspirin and Other COX-1 Inhibitors 63
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 62
The role of aspirin in cancer prevention 61
Nonsteroidal antiinflammatory drugs: past, present and future 61
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 61
Prostanoids, aspirin and related compounds 61
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 60
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 59
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 58
Cigarette smoking knowledge and perceptions among students in four italian medical schools 57
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 57
Diabetes: Does aspirin increase the risk of major bleeds? 56
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 56
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 55
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 54
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 53
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. 51
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? 49
Aspirin, 110 years later 48
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 48
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin 48
The P2Y12 receptor: no active metabolite, no party 47
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development 46
Mechanisms, consequences, and prevention of coronary graft failure 46
Selective COX-2 inhibitors: where do we go from here? 45
Antiplatelet Therapy 45
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 45
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 44
Measurement of Thromboxane Biosynthesis in Health and Disease 44
Aspirin at 120: Retiring, recombining, or repurposing? 44
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 42
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development 40
Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum 40
Nonsteroidal anti-inflammatory drugs and the heart 39
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now 39
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer 39
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance" 38
Role of Clinical Pharmacology in the Development of Antiplatelet Drugs 38
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 37
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 37
Precision antiplatelet therapy 34
Less Thromboxane, Longer Life 33
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials 32
Aspirin and Cancer 32
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. 31
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 31
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial 29
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 27
Totale 7.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.258
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.258
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202083 0 0 0 0 0 0 0 0 0 0 0 83
2020/2021770 71 83 9 75 104 74 73 23 87 15 124 32
2021/2022787 73 74 12 51 62 21 25 128 38 25 112 166
2022/20231.367 209 189 123 164 146 160 37 93 145 23 51 27
2023/2024797 23 235 35 81 36 53 57 30 14 34 91 108
2024/20251.405 34 41 123 51 103 43 32 116 240 135 301 186
Totale 7.170